NCT05067621View on ClinicalTrials.gov

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 17, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

January 31, 2027

Conditions
Type 2 Diabetes MellitusImpaired Glucose ToleranceNon-Alcoholic Fatty Liver DiseaseObesity, Childhood
Interventions
DRUG

Semaglutide Pen Injector

Semaglutide (Wegovy) pen is a subcutaneous injection that contains 2.4mg/0.75mL of active ingredient. The injection pen can deliver doses of 0.24mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg.

DRUG

Placebo

Injection pen contains excipients.

Trial Locations (1)

06511

RECRUITING

Pediatric Diabetes Center, New Haven

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Yale University

OTHER

NCT05067621 - Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease | Biotech Hunter | Biotech Hunter